ViaCell Investment Perspective

The answer is red ink and plenty of it. Operating and ret results are "mired" in red ink and at least one investor tipped off the Motley Fools about perceived management blunders.
Bad news, right? Well, not necessarily. The folks at Motley Fool eventually come down on the side of Via Cell. Here's an excerpt of their analysis:
Meanwhile, the firm has cut costs in an effort to accelerate its march to profitability. Losses for the quarter amounted to just $0.09 per share, half of last year's Q2 loss, and less than analysts predicted. Granted, most of the cost-cutting came in from a single one-time item: a "$2.2 million credit related to a reduction in contingent liabilities recorded with the acquisition of Kourion Therapeutics in 2003."You can read the whole piece here.
<< Home